Company profile for Argenx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to ...
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Laarderhoogtweg 25 1101 EB Amsterdam
Telephone
Telephone
+32 9 310 34 00
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/18/3190471/0/en/argenx-Announces-Results-of-Extraordinary-General-Meeting-of-Shareholders.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/10/30/3177052/0/en/argenx-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
30 Oct 2025

https://www.fiercepharma.com/pharma/argenx-pulls-back-curtain-vyvgarts-seronegative-win-cmo-underlines-mission-leave-no

FIERCE PHARMA
30 Oct 2025

https://www.globenewswire.com/news-release/2025/10/23/3171654/0/en/argenx-to-Report-Third-Quarter-2025-Financial-Results-and-Business-Update-on-October-30-2025.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/10/15/3166778/0/en/argenx-to-Highlight-Key-Data-and-Breadth-of-Immunology-Innovation-at-2025-AANEM-Annual-Meeting-and-MGFA-Scientific-Session.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3161194/0/en/argenx-announces-Extraordinary-General-Meeting-of-Shareholders-on-November-18-2025.html

GLOBENEWSWIRE
03 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty